Dear concerned reader,

Let me get straight to the point…

•  This killer germ has claimed 19,000 American lives a year.

•  Hospitals all over the country are bracing for a wave of lawsuits.

And one company stands to make a killing when the litigation frenzy begins!

Early investors could see gains of as much as 250%—no matter what the market is doing!

But you must get in on this fast-moving stock before its next earnings report in early May.

I’ll tell you all about it in my Special Report, Jackpot Justice: Make Triple-Digit Gains On Superbug Litigation.

First, some background…

The Cause

At first glance, it looked like a spider bite.

Then, it began to swell. It turned red and became painful to the touch. Then the fever started…

By the time the doctors diagnosed an infection with Methicillin-resistant Staphylococcus aureus—MRSA for short—it was too late.

On October 25, 2008, civil rights activist Norman Thomas died at Mercy Hospital in Baltimore, Maryland. He was 66 years old.

But Norman’s death was no isolated incident:

• On September 26, Alonzo Smith,an 18-year-old high school football player from Osceola County, Florida, complained about back pain. Three days later, the popular linebacker was dead. The cause of death: MRSA.

• On October 13, a high school senior in Virginia died of the bacterium.

• On December 12, Cody Shrout of Volusia County, Florida, succumbed to a drug-resistant staph infection. The 12-year-old had chickenpox antibodies in his blood. But the likely cause of death was Methicillin-resistant Staphylococcus aureus.

MRSA

It’s not just the old and the young that die of this antibiotic-resistant “Superbug”.

In 2003, Grant Hill, a professional basketball player with the Phoenix Suns and seven-time NBA All Star, contracted MRSA on his ankle.

His temperature climbed so high, it nearly killed him.

Hill survived—after a week in the intensive care unit.

He was lucky.

Because in 2005 alone, MRSA caused more than 94,000 life-threatening infections… and nearly 19,000 deaths in the United States!

That’s more deaths than those caused by AIDS…

or breast cancer…

or even auto accidents.

In fact, MRSA has claimed so many victims that 12 states are now proposing mandatory MRSA testing of all hospital patients. (Most hospitals only check the “at-risk” patients.)

Washington State in particular is pushing hard for new legislation.

With good reason…

Over the past decade, the number of Washington hospital patients infected with this frightening, antibiotic-resistant germ has SOARED—from 141 a year to 4,723!

And that’s exactly why one particular company is focusing their efforts on Washington State… creating an incredible opportunity for investors.

It’s vital you get your hands on shares of this company right now as a dozen state governments across the country are working on similar legislation.

Because that could send this company’s sales through the roof!

You can use this perfect storm of epidemic and legislative process to create gains of 50, 100, maybe even 250%.

Here’s how… 

More deaths per year than AIDS

According to the Journal of the American Medical Association, MRSA caused more than 94,000 life-threatening infections in just one year.

In 2005, nearly 19,000 people died of the infection in America alone.

Worse… experts believe that many cases are never reported.

Healthcare workers in are often carriers of MRSA, potentially putting patients at risk.

But it’s not just hospital transmissions that are driving the epidemic.

Newer, more dangerous MRSA strains have developed outside hospitals.

They breed virtually everywhere skin comes into contact with walls, furniture, exercise equipment… and affect otherwise healthy people of all ages.

The “bug” can be transferred by brushing against people, sharing towels or clothes… even through shaking hands.

It can slip into breaks in the skin as tiny as a mosquito bite and be contracted even by simple, non-invasive procedures…

Such as an MRI scan.

On April 17, 2006, fifteen-year-old Nile Calvin Moss got infected during an outpatient visit to a hospital where he under went an MRI.

After leaving the hospital, Nile developed a high temperature.

Like many Americans, his parents had never heard of MRSA until their healthy son succumbed to the infection in less than 72 hours from the first sign of a fever.

2.3 million carriers

Methicillin-resistant Staphylococcus aureus (MRSA) refers to types of staph that are resistant to many antibiotics due to over-prescription and improper usage…

Approximately 0.8% of the U.S. population is "colonized" with MRSA.

That works out to over 2.3 millions carriers with a 30-60% risk of full-blown infection.

Infections are increasing in frequency—and proving resistant to a wider range of antibiotics.

The Effect

The Center for Disease Control reports that each year, 1.7 million Americans contract a “Hospital-Acquired Infection” like MRSA.

Over 100,000 people die as a result.

In the United States, these infections add an estimated $30.5 billion to the nation’s hospital costs each year.  

If you’ve spent any time in the U.S., you know what that means…

Litigation!

On October 8, Dr. Betsy McCaughey, a former Lieutenant Governor of New York State and Founder/Chairman of the Committee to Reduce Infection Deaths, released a handbook on combating hospital-acquired infections.

“Hospital infection is the next asbestos, the next major cause of class action lawsuits, and the compendium will be the trial lawyer’s bible,” Dr. McCaughey said.

Hospitals that fail to adhere to its guidelines are vulnerable to legal action… and could end up paying huge damage awards.

Jackpot justice

Trial lawyer-driven asbestos litigation was the longest-running and most lucrative mass tort in history.

But MRSA could be just as profitable for litigation lawyers.

Nothing is better suited to litigation than hospital infections. Especially infections that have sudden, dramatic and potentially lethal outcomes.

Like MRSA.

Think it couldn’t happen? It already has…

In January 2005, a federal jury awarded two former Bucks County, Pennsylvania, prison inmates a whopping $1.2 million after finding their “civil rights were violated when they contracted a flesh-eating staph infection” in the jail in 2001 and 2002.

In October 2007, a New York woman whose 12-year-old son died from MRSA announced that she was suing a city hospital for $25 million.

And on January 6, in Brooksville, Florida, a widow filed court papers that blame local healthcare providers for her husband’s death from a virulent staph infection.

The number of lawsuits is set to escalate because no matter how sterile instruments and hospital equipment are kept, there will always be room for infection.

But while hospitals are unable to completely eradicate potential for exposure, they can test patients specifically for the worst-case scenario.

The Opportunity

There are a number of methods to test for MRSA.  Some take several days to get results… during which patients could die!

Last year, the FDA cleared the first rapid blood test. BD GeneOhm StaphSR, made by BD Diagnostics, delivers results in two hours.

But the FDA warns that the new test should be used only in patients suspected of a staph infection. And it shouldn’t be used as the sole basis for MRSA diagnosis.

And BD Diagnostics is just a small division of Becton, Dickinson and Co.—a $7 billon-a-year company, for whom even a successful MRSA test is just a drop in the bucket.

To investors, there’s a limited upside for the stock price.

But I’ve found a small cap where even
limited success could translate into huge gains…

As states push for mandatory testing laws to shield their healthcare systems from rampant litigation, this company’s product will see big demand…

It allows hospitals to do their testing in-house, instead of contracting a lab and waiting several days for results.

This small, $590 million-a-year company’s testing platform allows nearly any user to nearly instantly test for MRSA and several other biological threats like anthrax and even bubonic plague!

Doctors can have their test results in less than an hour… fifty minutes to be exact!… and at a fraction of the cost.

You need to act now

It is vital that you get your hands on my Special Opportunity Report, Jackpot Justice: Make Triple-Digit Gains On Superbug Litigation, and buy shares of this company right now.

With the vultures circling in Washington, state governments across the country are working on legislation that could send this company’s sales through the roof.

But now, legislators in states like Washington, Illinois and Pennsylvania are demanding hospitals go further. They want every patient who walks, staggers, or is carried into a hospital, tested.

It’s the only way to prove that that patient was infected before he entered the hospital!

Quick and inexpensive in-house testing is the only option.

Hospitals and healthcare providers will have to bite the bullet and spend hundreds of thousands on MRSA tests.

Or lose billions on class-action litigation!

The technology developed by this company will allow every emergency department, intensive care unit, nursing home, and even individual doctor’s offices to test their patients for MRSA.

Investors who get in before the company’s next earnings report — and take advantage of the company’s current low share price — will reap the largest rewards!

Its MRSA test sales more than quadrupled over the past year.

Cash flow is expected to be positive on the year, a significant sign of strength for any research-intensive company.

With a little help from our friends in the legislature, triple-digit gains are not just possible… but highly likely.

But you need to buy shares right now.

Governments of all sizes from across the country are looking at ways to stimulate the economy. Creating increased healthcare laws is sure to be one of their favorite vote-creating methods.

And this is just one of the opportunities I’m working on…

Why buy stocks—ANY stocks!—now?

The chaos of the past few weeks has shown us one thing…

No matter where the overall markets are headed, there are LOTS of ways to make money.

My analysts and I can show you, step by step, how to protect your current holdings… and pile up a fortune.

Safely. Rapidly. Logically.

And without fear.

You won’t be alone. Already, more than 250,000 investors have read and profited from our recommendations and coverage… thousands read my free TFN eNews e-letter every single day to stay on top of their investments.

A History of Timely Advance Warnings

My name is J. Christoph Amberger.

I predicted the current economic downturn in a book I wrote back in 2005, called Hot Trading Secrets.

About J. Christoph Amberger Mr. Amberger has issued predictive research reports like this one for many years to over 20 million readers. His past predictions have proved uncannily accurate — and profitable! Formerly the Executive Publisher of the successful financial newsletter Taipan, in December 2007 he launched his new, innovative research service, Today’s Financial News or simply, TFN. Some have argued “Tomorrow’s Financial News” might actually be more accurate! Where this international research network has reached into markets all over the world, his brand-new TFN premium service Hot Stock Confidential takes it several steps further… Not only with in-depth research… But now with the ability to deliver up-to-the-minute market news, recommendations, and urgent alerts as fully and frequently as you’ve come to expect from today’s advanced technology.

Since then, I’ve had many opportunities to issue warnings like this. Like in early September 2007, when I was speaking to a room full of skeptical investors at the 2007 Money Show in Washington, D.C.

A week before stock markets in China posted record highs, I forecasted a catastrophic downturn in Chinese equities.

Today, the Shanghai stock exchange is trading at just a third of its 2007 valuation.

On July 15, I warned our readers that oil prices were headed for a severe correction. People laughed and shook their heads.

And why not: After all, oil posted its all-time high of $147 that week.

We recommended our readers buy shares in select U.S. refinery stocks: These companies had been crushed as crude oil prices ate up their profit margins — and would certainly profit from a reversal of the trend.

Readers who took our advice saw shares in the refiners we recommended soar by up to 80% within just a few weeks… as oil prices began to plunge.

In October, I asked my editors to develop a strategy to safely profit from an unexpected drop in gold prices. Our “plunge protection” insurance surged over 63% in less than two weeks…

And in November 2008, I predicted that Russia’s Gazprom would cut Ukraine off from natural gas deliveries… causing a dramatic energy crisis in Western Europe.

So you see, we’ve a pretty darn good track record of calling scenarios just like this.

My assessment of this situation?

There’s No Time to Lose!

We want you to make the most you can off this life-saving technology.

Our Special Report, Jackpot Justice: Make Triple-Digit Gains On Superbug Litigation, will reveal EXACTLY how to make money on the coming MRSA epidemic.

If you get in by May 5, you’ll have plenty of time—and room at the top—to profit!

Why May 5?

Because, though the definite date has not been announced as of this writing, history shows us that this company will be announcing fiscal 2008 Q4 earnings in early May.

All indications show that the results will show a banner year for this company…

… and you want to be in position to reap the rewards!

Crisis and Opportunity

At TFN, our approach is straightforward: Provide our readers with profitable investment and trading recommendations… no matter what the overall markets are doing… through our elite premium research service, Hot Stock Confidential.

While markets crashed, our stock experts generated fast, safe, reliable gains on both the U.S. and overseas markets. Just take a look…

• 40.3% on Pyramid Oil Company (PDO) in 9 trading days…
• 50.2% on SPDR Gold Trust Jan 85 puts (KFFMG) in 24 trading days…
• 23.7% on Geron Corporation (GERN) in 16 trading days…
• 47.9% on Ford (F) in 27 trading days…
• 71.9% on Under Armour Jan 30 Puts (UAMF) in 5 trading days…
• 26.7% on Synta Pharmaceuticals (SNTA) in 21 trading days…
• 79.6% on Boeing Feb 55 puts (BANK) in 4 trading days…
• 38.4% on Alon USA Energy (ALJ) in 31 trading days…
• 35% on Oshkosh Corporation (OSK) in 11 trading days…
• 87.1% on National City Jan 2.5 Calls (NCCAZ) in just 1 trading day…
• 51.2% on Aastrom Biosciences (ASTM) in 29 trading days…
• 65.9% on CitiGroup (C) in 2 trading days…
• 41.9% on Nymox Pharmaceuticals (NYMX) in 21 trading days…
• and 83.2% on Altria 2008 Nov 22 17.00 Calls (MOKR) in a single day.

Now let me ask you a personal question…

What have your other newsletters been doing for you lately?

Many investors are wondering these days if they should they stay in the markets at all. Maybe it would be less painful to sell what’s left of their stock portfolios, close their eyes, and hope for the best.

Honestly, I’ve had a moment or two like that myself.

But then I looked at the markets and realized… There’s no way not to make money on fluctuations of 3%… 5%… even 10% and more in a single day… up and down and back up again!

What the markets have done for us is lowered our capital at risk.

Think about it…

Instead of taking your chances on a $60 stock for a 20% gain, you’re now able to trade that same stock for just $30… $15… or even $5.

For investors, this is a once-in-a-lifetime opportunity to build legacy wealth for pennies on the dollar.

For traders, trading the actual shares of companies has become almost as cheap as trading options used to be!

The risk may be the same in the short term… but the chances of exponential payback have increased along with volatility.

It’s a Matter of Strategy!

Right now, we’re keeping our eyes on literally dozens of opportunities like this.

The stocks and options we select for Hot Stock Confidential Members we'd buy ourselves, even in a "normal" market… and would have no problem recommending to our relatives.

They’re companies whose insiders are buying… that have easy-to-understand business concepts, established markets, growing revenues and unique products.

Some, like our “Jackpot justice stock”, are making great progress in the fields of biotechnology… genetics… medical diagnostics. Long-term, they will make excellent investments.

But in the meantime, every small breakthrough… every successful step in the approval process… holds the potential for amazing short-term profits. Especially in volatile markets like this!

In many instances the daily trading volume of these companies is so light, a single story in the mainstream media… an Internet rumor… a line dropped on a bulletin board… could double or triple their average daily trading activity and push stock prices out of our advisable buying range.

Instant Alerts for Fast Gains

The key to successful investing in a market environment like this is timing: The instant an opportunity arises, we notify you by special dedicated newsfeed or email.

To maximize your potential returns, it’s essential that you’re able to get out as soon as we issue a sell alert.

That’s how Hot Stock Confidential Members had the opportunity to cash in on gains like 41.8% on Nymox Pharmaceutical, 51.2% on Aastrom Biosciences, 38.4% on Alon USA, 26.7% on Synta Pharmaceuticals, 40.3% on Pyramid Oil Company and 83.2% on Altria 2008 Nov 22 17.00 Calls.

You can count on at least one breaking profit opportunity each week… on top of timely buy and sell alerts.

And we’ll provide you with concise updates on each and every open position in our Hot Stock Confidential tracking portfolio.

Plus we’ll give you access to exclusive special reports— all via your email—to your cellphone, Blackberry, or any other digital information medium.

For a report like Jackpot Justice: Make Triple-Digit Gains On Superbug Litigation, others may charge you $99… or even $199, but I’ll give it to you absolutely free with your Membership to Hot Stock Confidential.

And that’s just one of the critical wealth-building positions you must be in right now.

And remember… it’s crucial that you act NOW.

A Wealth of Actionable Investment Information

Besides Jackpot Justice: Make Triple-Digit Gains On Superbug Litigation, just a few of the other HSC Special Reports you’ll receive include:

Turmoil Stocks—Three Explosive Energy Stocks That Could Double Your Money Before 2010 (A $99 value!)
This report contains details on how the recent shakeup in the Urkraine means big money for these 3 small energy players — and massive gains for investors!

The 3 Hottest Stem Cell Stocks Under $5 (A $99 value!)
This sector is hot, hot, hot as the market anticipates the federal funding flowing in. And these 3 incredibly cheap stocks could be your ticket to triple-digit gains!

Profit From the Aging of America (A $99 value!)
This report outlines 3 stocks that will be propelled upward by sheer demographic pressure — no matter where the rest of the market is headed!

And you’ll receive access to every new Research Report we write the instant they’re published!

But that’s not all…

As a Member of Hot Stock Confidential, you’ll receive regular Special Research Reports, weekly Hot Stock alerts and portfolio updates, timely buy and sell notifications, a daily TFN eNews alert—including weekly Editor’s PICs—and full access to our TodaysFinancialNews.com information portal and the HotStockConfidential.com Members-only website.

Now you know how much a research service like this would typically set you back—$799, $999… or even $1,899 a year. And frequently they provide just one or two recommendations a month.

As a Member of Hot Stock Confidential, you’ll get all of our Reports, Alerts and valuable research for just $299 a year—if you accept this offer today!

Just $299… That’s about what you'd expect to pay for just the three of Research Reports you’ll get with your Membership—not to mention the investment recommendations you’ll receive at LEAST once a week.

How can this offer get any better?

Try us out for 90 days with our special auto-renew rate of just $79. You can’t beat that price!

And with the auto-renew option, you won’t get those annoying renewal emails. You’ll receive Hot Stock Confidential uninterrupted until you tell us to stop.

Order now and you’ll get instant access to our confidential report, Jackpot Justice: Make Triple-Digit Gains On Superbug Litigation PLUS our entire investment library of Research Reports, as well as all of our weekly Hot Stock Picks and Buy/Sell Alerts… for simply $299 for one year or a low $79 for 90 days with our auto-renew rate.

What Do You Have To Lose?

I would hate for you to miss out on this opportunity, but I know times are uncertain and you are careful how you spend your money.

I know I need to earn your trust.

That’s why I insist you take a full 45 days to put Hot Stock Confidential to the test.

If you don’t like what you’re reading during that time, you can cancel for a full refund.

That translates into an absolute minimum of 6 trading recommendations… on top of those we make available to you in our confidential Special Research Reports.

Should you decide that Hot Stock Confidential is not for you during this period, all you have to do is let us know and we’ll reimburse every nickel of your Membership fee. Anytime after the 45 days, your refund will be prorated.

That’s my promise to you.

May 5 is fast approaching…

Please, act now before the window of opportunity to make maximum gains with this life-saving company closes for good.

You have absolutely nothing to lose.

Become a Member of Hot Stock Confidential and the TFN Profit Network today by selecting the button below. Or if you'd prefer, call us directly at 1-877-465-1416.

Best regards,

J. Christoph Amberger
Executive Publisher
Hot Stock Confidential
January 2009

P.S.  Order today and you’ll receive access to the Special Reports, Jackpot Justice: Make Triple-Digit Gains On Superbug Litigation, Three Explosive Energy Stocks That Could Double Your Money Before 2010, The 3 Hottest Stem Cell Stocks Under $5, Profit From the Aging of America and more! And you’ll get it all for the Hot Stock Confidential introductory rate of $299 for a full year—or pay just $79 for our auto-renew rate for 90 days!